Long-term disease-free survival following surgery and active specific immunotherapy with allogeneic vaccine in a patient with high-risk malignant melanoma of the vulva

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 81, Issue 1, 1998, Pages 83-85

  Piura, Benjamin ^a   Meirovitz, Mihai ^a   Kedar, Igal ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Allogeneic specific antimelanoma vaccine; Specific immunotherapy; Vulval malignant melanoma

Indexed keywords

CIMETIDINE; MELANOMA VACCINE;

ADULT; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CASE REPORT; DRUG MEGADOSE; FEMALE; HUMAN; IMMUNOTHERAPY; INGUINAL LYMPH NODE; LYMPH NODE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; VULVA; VULVECTOMY;

EID: 0032189072     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(98)00156-0     Document Type: Article

References (14)

1. [1] Dunton CJ, Kautzky M, Hanau C. Malignant melanoma of the vulva: A review. Obstet Gynecol Surv 1995;50:739-45.
2. [2] Piura B, Egan M, Lopes A, Monaghan JM. Malignant melanoma of the vulva: A clinicopathologic study of 18 cases. J Surg Oncol 1992;50:234-40.
3. [3] Tasseron EWK, van der Esch EP, Hart AA, Brutel de la Riviere G, Aartsen EJ. A clinicopathological study of 30 melanomas of the vulva. Gynecol Oncol 1992;46:170-5.
4. [4] Raber G, Mempel V, Jackisch C, Hundeiker M, Heinecke A, Kurzl R, Glaubitz M, Rompel R, Schneider HPG. Malignant melanoma of the vulva. Report of 89 patients. Cancer 1996;78:2353-8.
5. [5] Look KY, Roth LM, Sutton GP. Vulvar melanoma reconsidered. Cancer 1993;72:143-6.
6. [6] Trimble EL, Lewis JL, Williams LL, Curtin JP, Chapman D, Woodruff JM, Rubin SC, Hoskins WJ. Management of vulvar melanoma. Gynecol Oncol 1992;45:254-8.
7. [7] Mitchell MS, Kan-Mitchell J, Kemf RA, Harel W, Shau H, Lind S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988;48:5883-93.
8. [8] White WB, Ballow M. Modulation of suppressor-cell activity by cemitidine in patients with common variable hypogammaglobulinemia. N Engl J Med 1985;312:198-202.
9. [9] Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Nat Cancer Inst 1993;85:622-32.
10. [10] Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma -A preliminary report. N Eng J Med 1988;319:1676-80.
11. [11] Oldham RK, Blumenschein G, Schwartzberg L, Birch R, Arnold J. Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. Mol Biother 1992;4:4-9.
12. [12] Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
13. [13] Livingston PO, Ragupathi G. Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother 1997;45:10-9.
14. [14] Berd D, Maguire Jr. HC, Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997;15:2359-70.